Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Gain Therapeutics (Nasdaq: GANX) announced a poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from October 23-25, 2024. The poster will showcase the use of Gain's Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors.
DDR2 is implicated in various cancer types and plays a important role in tumor progression. Allosteric small molecule inhibitors have the potential to overcome resistance and offer improved selectivity and safety compared to traditional kinase inhibitors. The presentation, titled 'Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2)', will be given by Sara Cano-Crespo, Ph.D., from Gain Therapeutics during the Molecular Targeted Agents poster session on October 23, 2024, at 11am CEST.
Gain Therapeutics (Nasdaq: GANX) ha annunciato una presentazione di poster al 36° Simposio EORTC-NCI-AACR sui Target Molecolari e sulle Terapie per il Cancro a Barcellona, Spagna, dal 23 al 25 ottobre 2024. Il poster mostrerà l'uso della piattaforma Magellan di Gain per scoprire nuovi inibitori allosterici del recettore discoidina di dominio 2 (DDR2).
Il DDR2 è implicato in diversi tipi di cancro e gioca un ruolo importante nella progressione tumorale. Gli inibitori allosterici a piccole molecole hanno il potenziale di superare la resistenza e offrire una maggiore selettività e sicurezza rispetto agli inibitori delle chinasi tradizionali. La presentazione, intitolata 'Identificazione di inibitori allosterici mirati al Recettore Discoidina di Dominio 2 (DDR2)', sarà tenuta da Sara Cano-Crespo, Ph.D., di Gain Therapeutics durante la sessione di poster sugli Agenti Molecolari Mirati il 23 ottobre 2024, alle 11:00 CEST.
Gain Therapeutics (Nasdaq: GANX) anunció una presentación de póster en el 36° Simposio EORTC-NCI-AACR sobre Objetivos Moleculares y Terapias contra el Cáncer en Barcelona, España, del 23 al 25 de octubre de 2024. El póster destacará el uso de la plataforma Magellan de Gain para descubrir nuevos inhibidores alostéricos del receptor discoidina de dominio 2 (DDR2).
El DDR2 está implicado en varios tipos de cáncer y juega un papel importante en la progresión tumoral. Los inhibidores alostéricos de pequeñas moléculas tienen el potencial de superar la resistencia y ofrecer una mejor selectividad y seguridad en comparación con los inhibidores de quinasas tradicionales. La presentación, titulada 'Identificación de inhibidores alostéricos dirigidos al Receptor Discoidina de Dominio 2 (DDR2)', será presentada por Sara Cano-Crespo, Ph.D., de Gain Therapeutics durante la sesión de póster de Agentes Moleculares Dirigidos el 23 de octubre de 2024, a las 11 a.m. CEST.
Gain Therapeutics (Nasdaq: GANX)는 2024년 10월 23일부터 25일까지 스페인 바르셀로나에서 열리는 제36회 EORTC-NCI-AACR 분자 표적 및 암 치료 심포지엄에서 포스터 발표를 진행한다고 발표했습니다. 이 포스터는 Gain의 마젤란 플랫폼을 활용하여 새로운 디스코이딘 도메인 수용체 2 (DDR2) 알로스테릭 억제제를 발견하는 내용을 다룰 것입니다.
DDR2는 다양한 암 유형에 관련되어 있으며 종양 진행에서 중요한 역할을 합니다. 알로스테릭 소분자 억제제는 저항성을 극복하고 전통적인 키나제 억제제에 비해 개선된 선택성과 안전성을 제공할 수 있는 잠재력을 가지고 있습니다. '디스코이딘 도메인 수용체 2 (DDR2)를 표적으로 하는 알로스테릭 억제제의 식별'이라는 제목의 발표는 Gain Therapeutics의 Sara Cano-Crespo, Ph.D.에 의해 2024년 10월 23일 오전 11시 CEST 동안 분자 표적 제제 포스터 세션에서 진행될 예정입니다.
Gain Therapeutics (Nasdaq: GANX) a annoncé une présentation de poster au 36e Symposium EORTC-NCI-AACR sur les cibles moléculaires et les thérapies anticancéreuses à Barcelone, Espagne, du 23 au 25 octobre 2024. Le poster mettra en avant l'utilisation de la plateforme Magellan de Gain pour découvrir de nouveaux inhibiteurs allostériques du récepteur Discoidin de domaine 2 (DDR2).
Le DDR2 est impliqué dans divers types de cancer et joue un rôle important dans la progression tumorale. Les inhibiteurs allostériques de petites molécules ont le potentiel de surmonter la résistance et d'offrir une meilleure sélectivité et sécurité par rapport aux inhibiteurs de kinases traditionnels. La présentation, intitulée 'Identification des inhibiteurs allostériques ciblant le récepteur Discoidin de domaine 2 (DDR2)', sera donnée par Sara Cano-Crespo, Ph.D., de Gain Therapeutics lors de la session de posters sur les agents ciblés moléculaires le 23 octobre 2024 à 11h CEST.
Gain Therapeutics (Nasdaq: GANX) kündigte eine Poster-Präsentation beim 36. EORTC-NCI-AACR-Symposium zu molekularen Zielen und Krebstherapeutika in Barcelona, Spanien, vom 23. bis 25. Oktober 2024 an. Das Poster wird den Einsatz von Gains Magellan-Plattform zur Entdeckung neuer allosterischer Inhibitoren des Discoidin-Domänen-Rezeptors 2 (DDR2) vorstellen.
Der DDR2 ist an verschiedenen Krebsarten beteiligt und spielt eine wichtige Rolle im Tumorwachstum. Allosterische kleine Molekülinhibitoren haben das Potenzial, Resistenzen zu überwinden und bieten eine verbesserte Selektivität und Sicherheit im Vergleich zu traditionellen Kinase-Inhibitoren. Die Präsentation mit dem Titel 'Identifizierung allosterischer Inhibitoren, die den Discoidin-Domänen-Rezeptor 2 (DDR2) anvisieren', wird von Sara Cano-Crespo, Ph.D., von Gain Therapeutics während der Postersitzung zu molekularen zielgerichteten Mitteln am 23. Oktober 2024 um 11 Uhr CEST gehalten.
- Presentation of novel cancer therapy research at a major oncology symposium
- Potential for improved cancer treatment through allosteric DDR2 inhibitors
- Demonstration of the capabilities of Gain's Magellan platform in drug discovery
- None.
BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the use of the Company’s Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors will be presented at the 36th EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics being held October 23-25 in Barcelona, Spain. DDR2 displays aberrant expression and mutations across various cancer types and is involved in critical processes in tumor progression, including proliferation, migration, invasion, metastasis, epithelial-mesenchymal transition, and chemotherapy resistance. Allosteric small molecule inhibitors have the potential to overcome resistance and offer enhanced selectivity and safety compared to traditional kinase inhibitors.
ENA 2024 stands as the drug development and translational research meeting, giving the spotlight to preclinical and phase I studies, ensuring in-depth scientific discussions on the latest developments in targets and drugs.
Title: Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2)
Presenting Author: Sara Cano-Crespo, Ph.D., Gain Therapeutics
Poster Session: Molecular Targeted Agents
Date and Time: Wednesday, October 23, 2024, 11am CEST
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended June 30, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com
Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
What is Gain Therapeutics (GANX) presenting at the 36th EORTC-NCI-AACR Symposium?
When and where is the 36th EORTC-NCI-AACR Symposium taking place?
What is the potential benefit of allosteric DDR2 inhibitors discovered by Gain Therapeutics (GANX)?
Who is presenting the poster for Gain Therapeutics (GANX) at the symposium?
